Gentulizumab
- Generic Name
- Gentulizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05263271
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT05221385
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Jian Zhang, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath